* BEIGENE INITIATES GLOBAL PHASE 2 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MATURE T-AND NK-CELL LYMPHOMAS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)


00


Reuters

17 Related Articles from 2018-04-16